Ricolinostat, a selective HDAC6 inhibitor, was well tolerated and moderately effective in combination with bortezomib (Vogl et al., 2017) and the immunomodulator lenalidomide plus dexamethasone (Yee et al., 2016) in refractory multiple myeloma. Here, HDAC6 is linked to plasma cell myeloma.